Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters

BACKGROUND: Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent‐line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Katsui, Kuniaki, Ogata, Takeshi, Watanabe, Kenta, Katayama, Norihisa, Kuroda, Masahiro, Kiura, Katsuyuki, Hiraki, Takao, Maeda, Yoshinobu, Toyooka, Shinichi, Kanazawa, Susumu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333825/
https://ncbi.nlm.nih.gov/pubmed/32364685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados